Published On: Wed, Oct 19th, 2016

Broker Changes For Kite Pharma, Inc. (NASDAQ:KITE)


Recently stock market analysts have updated their consensus ratings on shares of Kite Pharma, Inc. (NASDAQ:KITE).

Most recent broker ratings

10/17/2016 – Kite Pharma, Inc. had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 72 price target on the stock.

10/10/2016 – Kite Pharma, Inc. had its “buy” rating reiterated by analysts at Canaccord Genuity. They now have a USD 75 price target on the stock.

10/07/2016 – Kite Pharma, Inc. had its “buy” rating reiterated by analysts at Goldman Sachs. They now have a USD 70 price target on the stock.

10/06/2016 – Kite Pharma, Inc. had its “neutral” rating reiterated by analysts at BTIG Research.

10/06/2016 – Kite Pharma, Inc. had its “buy” rating reiterated by analysts at Stifel Nicolaus. They now have a USD 74 price target on the stock.

09/27/2016 – Kite Pharma, Inc. had its “equal weight” rating reiterated by analysts at Barclays. They now have a USD 65 price target on the stock.

09/27/2016 – Kite Pharma, Inc. had its “outperform” rating reiterated by analysts at FBR Capital Markets. They now have a USD 78 price target on the stock.

08/09/2016 – Kite Pharma, Inc. had its “buy” rating reiterated by analysts at Maxim Group. They now have a USD 77 price target on the stock.

08/09/2016 – Kite Pharma, Inc. had its “outperform” rating reiterated by analysts at Mizuho. They now have a USD 80 price target on the stock.

06/02/2016 – Raymond James began new coverage on Kite Pharma, Inc. giving the company a “outperform” rating. They now have a USD 61 price target on the stock.

03/17/2016 – Kite Pharma, Inc. had its “buy” rating reiterated by analysts at SunTrust. They now have a USD 70 price target on the stock.

02/25/2016 – Citigroup began new coverage on Kite Pharma, Inc. giving the company a “buy” rating. They now have a USD 67 price target on the stock.

02/01/2016 – RBC Capital began new coverage on Kite Pharma, Inc. giving the company a “outperform” rating. They now have a USD 85 price target on the stock.

12/15/2015 – Kite Pharma, Inc. was upgraded to “buy” by analysts at Standpoint Research. They now have a USD 100 price target on the stock.

11/02/2015 – Kite Pharma, Inc. had its “outperform” rating reiterated by analysts at Cowen.

Kite Pharma, Inc. has a 50 day moving average of 55.87 and a 200 day moving average of 52.55. The stock’s market capitalization is 2.46B, it has a 52-week low of 38.41 and a 52-week high of 89.84.

The share price of the company (NASDAQ:KITE) was up +0.32% during the last trading session, with a high of 50.14 and the volume of Kite Pharma, Inc. shares traded was 1332654.